Asymptomatic hyperuricemia and chronic kidney disease: Narrative review of a treatment controversial.

ABSTRACT: Today there is plausible evidence both on experimental and epidemiological basis, that hyperuricemia represents a risk factor for the development and progression of chronic kidney disease (CKD). Nevertheless, the role of serum uric acid lowering treatment in CKD is still a matter of serious controversy. Review of randomised controlled trials, suggests that there may be an improvement of renal function with allopurinol treatment in CKD stage 3-5. However, these studies have included a relatively limited number of participants and provide insufficient information on adverse events and on the incidence of the end stage renal disease. Therefore, before adequately powered randomised, placebo-controlled trials are completed we cannot recommend treating asymptomatic hyperuricemia in patients with CKD.

SUBMITTER: Eleftheriadis T 

PROVIDER: S-EPMC5512148 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature